Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.53 |
| ▸ | ACLY | P53396 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425134 | 0.92 | NPC1 (0.59) | NPC1RAB9ANPSR1MAPTPTPN5 | |
| SCHEMBL5196001 | 0.90 | IKBKB (0.52) | NPC1RAB9ANPSR1MAPTPTPN5 | |
| SCHEMBL5192448 | 0.90 | NPC1 (0.50) | NPC1RAB9ANPSR1MAPTPTPN5 | |
| SCHEMBL5197554 | 0.88 | NPC1 (0.52) | NPC1RAB9ANPSR1MAPTPTPN5 | |
| SCHEMBL5195979 | 0.87 | CHEK1 (0.55) | NPC1RAB9ANPSR1MAPTPTPN5 | |
| SCHEMBL5194731 | 0.85 | NPSR1 (0.45) | NPC1RAB9ANPSR1MAPTPTPN5 | |
| SCHEMBL5411364 | 0.84 | HPGD (0.52) | NPC1RAB9ANPSR1MAPTKDM4E | |
| SCHEMBL5196748 | 0.83 | NPC1 (0.45) | NPC1RAB9ANPSR1MAPTPTPN5 | |
| SCHEMBL5192643 | 0.83 | ERO1A (0.41) | NPC1RAB9ANPSR1MAPTPTPN5 | |
| SCHEMBL5195431 | 0.81 | MAPT (0.43) | NPC1RAB9ANPSR1MAPTPTPN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | NPC1 1701/4885RAB9A 4414/4885NPSR1 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.